Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails in Phase IIa Trial

Dynavax Technologies shares fell more than 5 percent after the company reported that an asthma drug being jointly developed with AstraZeneca failed to meet endpoints in a mid-stage trial.

Read More »

BMS Teams with Two UK Research Groups to Create Lung Cancer Rule Book

Bristol-Myers Squibb is teaming up with Cancer Research UK and the Francis Crick Institute to create guidelines for immuno-oncology therapy development focused on lung cancer treatments.

Read More »

10X Genomics Prepares to Hire 200 New Employees, Move into Larger Facility

Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately held companies in the region with an earnings increase of more than 2,000 percent over a three-year period. As a result of that growth, the company optioned space in its town of Pleasanton, Calif.

Read More »

U.S. judge raises prospect of not approving CVS-Aetna deal

In an unusual move, a federal judge raised the prospect of not approving CVS Health Corp.’s deal to buy insurer Aetna Inc. – which has closed – during a routine portion of the legal process.

Read More »

Bayer To Slash 12,000 Employees, Aims To Strengthen Life Science Business

Bayer will cut 12,000 jobs as the company prepares a business overhaul, including an exit from the animal health division.

Read More »

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

Read More »

Merck Raised Prices Of Five Drugs In November 2018, Including Keytruda

Merck & Co. Inc. raised U.S. prices on five of the company’s drugs in November 2018 by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

Read More »

Teva Issues Recall of Tainted Blood Pressure Medicine

Teva Pharmaceutical has issued a voluntary recall for combination forms of the company’s blood pressure drug amlodipine due to cancer-causing impurities discovered in the tablets.

Read More »

Top Predictions for 2019 by Biopharma Execs

Biopharma executives were asked to predict what the next year might reveal.

Read More »

Roche buys U.S. biotech Jecure in race for liver disease drugs

Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom